Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORA-3 trial of lisaftoclax plus azacitidine in newly diagnosed acute myeloid leukemia
2024-516436-10-00Phase 3Authorised
- Sponsor
- Ascentage Pharma
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Lisaftoclax + azacitidine with Placebo + azacitidine (2 arms). Primary endpoint: Overall survival. Planned start Jun 2026; status: authorised.
02
Drugs
lisaftoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-516436-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516436-10-00.